CD19 and CD22 targeted CAR-T cells

BIOLOGICAL4 trials

Sponsors

Xinqiao Hospital of Chongqing, Chongqing Precision Biotech Co., Ltd, Kecellitics Biotech Company Ltd

Conditions

B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryLeukemia, B-cellLymphoma, B-Cell

Early Phase 1

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Xinqiao Hospital of ChongqingB-cell Lymphoma Recurrent, B-cell Lymphoma Refractory

Start: 2020-05-01End: 2023-05-01Target: 30Updated: 2020-03-11

Phase 1

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Chongqing Precision Biotech Co., LtdLeukemia, B-cell, Lymphoma, B-Cell

Start: 2020-08-25End: 2024-07-01Target: 40Updated: 2023-04-18

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Chongqing Precision Biotech Co., LtdLeukemia, B-cell, Lymphoma, B-Cell

Start: 2019-09-01End: 2024-07-01Target: 40Updated: 2023-04-18

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Kecellitics Biotech Company LtdLymphoma, B-Cell

Start: 2022-12-10End: 2025-12-10Target: 50Updated: 2022-12-14